Superworth

Vanda Pharmaceuticals VNDA

Drug Manufacturers - General, Healthcare
$3.88
+2.37%
Market cap
$234.6M
PE
n/m
a loss over the last year
Forward PE
n/m
not a meaningful number
Price to sales
1.0×
EV/EBIT
n/m
a loss over the last year
Revenue, 12 months
$229.3M
+8% on a year ago
Net margin
n/m
outside −100% to 100%
Free cash flow yield
−59.7%

Vanda Pharmaceuticals trades at 1.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $229.3M over the last twelve months, up 8% on a year earlier.

Charts

Financials

Income statement for VNDA, by quarter
Income statementQ4 FY23Q1 FY24Q2 FY24Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26
$45.3M−30%$47.5M−24%$50.5M+10%$47.7M+23%$53.2M+18%$50M+5%$52.6M+4%$56.3M+18%$57.2M+8%$51.7M+3%$50.5M−4%$69.8M+24%
Cost of revenue$3.5M−45%$3.4M−28%$2.7M−22%$2.6M−17%$2.6M−25%$3.5M+2%$2.7M+0%$3M+16%$3.8M+48%$3.2M−10%$3.6M+30%$4.2M+41%
Gross profit$41.8M−28%$44M−24%$47.7M+12%$45.1M+26%$50.6M+21%$46.5M+6%$49.9M+4%$53.3M+18%$53.4M+6%$48.6M+4%$47M−6%$65.7M+23%
R&D$24.3M+32%$21.2M+10%$16.7M+0%$16.8M+1%$19.8M−19%$35.7M+69%$22M+32%$22.6M+35%$29M+46%$28.4M−20%$37M+68%$27.6M+22%
SG&A$23.6M−28%$30.1M−17%$39.5M+39%$37.6M+52%$39.3M+66%$50.1M+67%$64.6M+64%$60.3M+60%$63M+60%$68.4M+37%$71.8M+11%$59.6M−1%
−$7.1M−$9.2M−$10.1M+254%−$11M+84%−$10.3M+45%−$41M+344%−$38.5M+280%−$31.3M+184%−$40.4M+293%−$50.2M+22%−$63.8M+66%−$23.5M−25%
Pre-tax income−$1.7M−$4.7M−$5.5M−$6.2M+5103%−$6.5M+291%−$37.4M+701%−$34.9M+533%−$28.4M+355%−$38M+485%−$48.4M+30%−$62.4M+79%−$22.4M−21%
$739K−73%−$518K−$998K−$920K+258%−$1.6M−$7.9M+1420%−$7.7M+670%−$5.8M+531%$103.2M$143K$129K$174K
Net income−$2.4M−$4.1M−$4.5M−$5.3M−$4.9M+105%−$29.5M+611%−$27.2M+502%−$22.6M+324%−$141.2M+2774%−$48.6M+65%−$62.5M+130%−$22.6M−0%
−$0.04−$0.07−$0.08−$0.09−$0.08+100%−$0.50+614%−$0.46+475%−$0.38+322%−$2.39+2888%−$0.82+64%−$1.04+126%−$0.37−3%
57.5M+1%57.8M+1%58.2M+1%58.3M+1%58.3M+1%58.5M+1%59M+1%59.1M+1%59.1M+1%59.5M+2%60.2M+2%60.5M+2%

Gross profit: 53 periods, Q2 FY10 to Q3 FY26: not printed by the filing, worked out from its own lines.

EPS, diluted: 10 periods, Q4 FY10 to Q4 FY25: quarter's net income to common over its shares, to the cent.

Diluted shares: 5 periods, Q4 FY10 to Q4 FY21: share-days: the 12-month average less the 9-month, weighted by days. 9 periods, Q4 FY11 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY14 and Q4 FY22: the earlier year to date counted no dilution: the quarter's basic count plus the later year to date's dilution.

From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.

Peers

Companies in Drug Manufacturers - General nearest Vanda Pharmaceuticals' size, closest first.

CompanyMarket capPEIts 10y median PEFwd PEP/SRevenue growthNet margin
VNDAVanda Pharmaceuticals$234.6Mn/m34.4×1.0×+8%n/m
NATRNatures Sunshine Products$211.5M11.9×20.2×0.4×+7%3.7%
CRMDCorMedix$420.1M2.5×4.0×0.9×+281%40.5%
ARVNArvinas$491.7M47.0×50.5×1.6×−15%2.9%
PBYIPuma Biotechnology$525.5M19.6×12.3×2.3×−3%11.6%
IRWDIronwood Pharmaceuticals$571.7M4.5×14.8×1.5×+26%33.4%
ZVRAZevra Therapeutics$599.8M10.9×12.2×4.4×+119%42.8%
LFVNLifevantage$73.5M14.7×19.4×0.4×−20%2.8%
COLLCollegium Pharmaceutical$770.9M19.1×19.1×1.0×+14%5.9%
ABUSArbutus Biopharma$791.4M5.1×5.6×4.4×n/m84.2%
SPROSpero Therapeutics$60.6M9.5×9.5×1.3×−3%15.7%
Peer median$508.6M11.4×13.5×1.4×+7%13.6%

More on Vanda Pharmaceuticals

Each number over time

Its groups

About

Industry
Drug Manufacturers - General
Sector
Healthcare

Valuation data, not investment advice. Prices as of .